{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:43:44Z","timestamp":1791150224227,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Immune checkpoint inhibitor (ICI) therapy plus chemotherapy has become a standard of care for patients with advanced non\u2010small cell lung cancer (NSCLC). Pre\u2010existing interstitial lung disease (ILD) is a risk factor for drug\u2010induced pneumonitis caused by chemotherapy or ICI monotherapy. However, clinical data in patients with pre\u2010existing ILD who received ICI therapy plus chemotherapy are limited. This study aimed to identify the risk factors for drug\u2010induced pneumonitis in patients with NSCLC treated with ICIs plus chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively reviewed the medical records of 160 consecutive patients who were diagnosed with NSCLC and treated with ICIs plus chemotherapy at Aichi Cancer Center Hospital between December 2018 and November 2020. Patients with a prior history of ICI treatment or thoracic radiotherapy were excluded from the analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 125 patients, pre\u2010existing ILD was observed in 20 patients (16.0%). Drug\u2010induced pneumonitis developed in 17 patients (13.6%), with a median time to onset of 19.3\u2009weeks (range, 1.6\u2013108.9\u2009weeks). In multivariate logistic analysis, pre\u2010existing ILD (odds ratio\u00a0=\u00a019.07, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.0001) and PEM exposure (odds ratio\u00a0=\u00a05.67, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.022) were identified as risk factors for the development of drug\u2010induced pneumonitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Pre\u2010existing ILD and pemetrexed exposure are risk factors for drug\u2010induced pneumonitis in patients with NSCLC.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1759-7714.14308","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T10:56:05Z","timestamp":1642589765000},"page":"724-731","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Risk factors for pneumonitis in patients with non\u2010small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis"],"prefix":"10.1111","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8909-5709","authenticated-orcid":false,"given":"Teppei","family":"Yamaguchi","sequence":"first","affiliation":[{"name":"Department of Thoracic Oncology Aichi Cancer Center Hospital  Nagoya Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Aichi Cancer Center Hospital  Nagoya Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Oya","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Aichi Cancer Center Hospital  Nagoya Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Aichi Cancer Center Hospital  Nagoya Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6701-8836","authenticated-orcid":false,"given":"Takaaki","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology Aichi Cancer Center Hospital  Nagoya Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitsugu","family":"Horio","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Aichi Cancer Center Hospital  Nagoya Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Inaba","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology Aichi Cancer Center Hospital  Nagoya Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Aichi Cancer Center Hospital  Nagoya Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,1,19]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30498-3"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.04.002"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.10.001"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.02.017"},{"issue":"9","key":"e_1_2_7_15_1","first-page":"5199","article-title":"Correlation of radiation pneumonitis history before Nivolumab with onset of interstitial lung disease and progression\u2010free survival of patients with pre\u2010treated advanced non\u2010small cell lung cancer","volume":"37","author":"Tamiya A","year":"2017","journal-title":"Anticancer Res"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.2035"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001170"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1255ST"},{"key":"e_1_2_7_19_1","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: November 27 2017. U.S. Department of Health and Human Services National Institute of Health National Cancer Institute. [cited 2021 December 15]. Available from:https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm."},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2011.11.001"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200710-1501OC"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2010.01907.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-0359"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168465"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2011.08.002"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyx010"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2010.04.014"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14217"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10182"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-009-9391-9"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2016.12.016"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13725"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.01.004"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.14308","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1759-7714.14308","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.14308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T02:24:24Z","timestamp":1693103064000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.14308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,19]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1111\/1759-7714.14308"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.14308","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,19]]},"assertion":[{"value":"2021-11-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}